Avison

Avison Biomedical is a biotechnology company focused on developing novel small molecule therapeutics for the treatment of inflammatory diseases and viral infections. The company's lead programs target the underlying mechanisms of cytokine storms and viral replication, with a particular emphasis on addressing unmet needs in respiratory and systemic inflammatory conditions. Founded by industry veterans from Hollis-Eden Pharmaceuticals, Avison leverages deep expertise in adrenal steroid chemistry to advance its pipeline of oral drug candidates. Their primary candidate, AVS-001, is designed to modulate the immune response without the broad immunosuppression typical of traditional corticosteroids. The company aims to provide effective treatments for patients suffering from hyper-inflammatory responses triggered by infectious agents.